Clinical trial
A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.
NCT04749485 is registered in ClinicalTrials.gov with Taizhou Hanzhong biomedical co. LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.
- Lead sponsor
- Taizhou Hanzhong biomedical co. LTD
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 8, 2018
- Completion date
- November 8, 2021
- Enrollment
- 119 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.